| review article | Q7318358 |
| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(09)70112-3 |
| P698 | PubMed publication ID | 19482548 |
| P2093 | author name string | David Chu | |
| Sanjaykumar Hapani | |||
| Shenhong Wu | |||
| P2860 | cites work | Tumor angiogenesis: therapeutic implications | Q27860595 |
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Role of angiogenesis in tumor growth and metastasis | Q29614309 | ||
| Quantitative synthesis in systematic reviews | Q29614894 | ||
| Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 | ||
| Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial | Q34555503 | ||
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Bowel perforation in non-small cell lung cancer after bevacizumab therapy | Q34594867 | ||
| Gastrointestinal perforations associated with interleukin-2 administration | Q35742912 | ||
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 | ||
| Managing patients treated with bevacizumab combination therapy. | Q36319038 | ||
| Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis | Q36721468 | ||
| Gastrointestinal perforation due to bevacizumab in colorectal cancer | Q36759132 | ||
| Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation | Q36784813 | ||
| Management of bevacizumab-associated bowel perforation: a case series and review of the literature | Q37007540 | ||
| Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 | Q37117085 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| Peptic ulcer perforation associated with steroid use. | Q38172413 | ||
| Selecting and appraising studies for a systematic review | Q41602557 | ||
| Emergency laparotomy for spontaneous intestinal and colonic perforations in cancer patients receiving corticosteroids and chemotherapy | Q42080905 | ||
| VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature | Q46231250 | ||
| Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer | Q46502913 | ||
| Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer | Q46972019 | ||
| [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery]. | Q53485924 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? | Q79484136 | ||
| What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? | Q80031889 | ||
| Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management | Q80257767 | ||
| Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab | Q80422514 | ||
| Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro | Q81735598 | ||
| Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) | Q82294729 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| bevacizumab | Q413299 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 559-568 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis | |
| P478 | volume | 10 |
| Q84897030 | "Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines" |
| Q36195933 | A Case Report of Gastrointestinal Hemorrhage and Perforation During Apatinib Treatment of Gastric Cancer |
| Q41939405 | A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab |
| Q37839831 | A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer |
| Q34956830 | A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours |
| Q36163040 | A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. |
| Q82657397 | A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites |
| Q34307924 | A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers |
| Q98226043 | A retrospective analysis of emergency surgery for cases of acute abdomen during cancer chemotherapy. Case series |
| Q36338069 | AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. |
| Q64982233 | Acute scrotal swelling following perforated rectal carcinoma with abscess formation. |
| Q38492121 | Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials |
| Q55433803 | Adverse events related to bevacizumab and the management principles in non-small cell lung cancer |
| Q40222366 | An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab |
| Q37856782 | Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. |
| Q34152125 | Anti-VEGF Cancer Therapy in Nephrology Practice |
| Q38020234 | Anti-angiogenic drug discovery: lessons from the past and thoughts for the future |
| Q45820306 | Antiangiogenic therapies: is VEGF-A inhibition alone enough? |
| Q37983389 | Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities |
| Q35009777 | Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review |
| Q91710473 | Antitumor Drug Combretastatin-A4 Phosphate Aggravates the Symptoms of Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice |
| Q37963955 | Benefit-risk assessment of bevacizumab in the treatment of breast cancer. |
| Q36248498 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence |
| Q39782817 | Bevacizumab and its use in epithelial ovarian cancer |
| Q35705156 | Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety |
| Q44029291 | Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials |
| Q43497234 | Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups |
| Q64230028 | Bevacizumab is associated with delayed anastomotic leak after low anterior resection with preoperative radiotherapy for rectal cancer: a case report |
| Q37415131 | Bevacizumab toxicities and their management in ovarian cancer |
| Q53735971 | Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma. |
| Q47689626 | Bevacizumab-associated gastrointestinal perforation |
| Q91658268 | Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab |
| Q51734559 | Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature. |
| Q37986306 | Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database |
| Q43550192 | Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. |
| Q37220438 | Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors |
| Q38260176 | Bevacizumab: a review of its use in advanced cancer |
| Q42206355 | Bilateral pneumothorax after bevacizumab-containing chemotherapy in fibrosarcoma |
| Q33895581 | Biological agents in gastrointestinal cancers: adverse effects and their management |
| Q38557035 | Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature |
| Q89075215 | Bowel Perforation Resulting in Necrotizing Soft-Tissue Infection of the Abdomen, Flank, and Lower Extremities |
| Q43135873 | Breaking down the evidence for bevacizumab in ovarian cancer |
| Q38859253 | Cancer therapy-related complications in the bowel and mesentery: an imaging perspective |
| Q38371293 | Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients |
| Q46260973 | Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab |
| Q38016098 | Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients |
| Q41896383 | Chemotherapy-induced enterocutaneous fistula after perineal hernia repair using a biological mesh: a case report |
| Q37822101 | Clinical predictors of bevacizumab-associated gastrointestinal perforation. |
| Q52656871 | Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer. |
| Q84676387 | Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study |
| Q60309783 | Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis |
| Q38014349 | Complications of oncologic therapy in the abdomen and pelvis: a review |
| Q38084265 | Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms |
| Q38948598 | Concurrent gastrointestinal perforation and pulmonary embolism due to bevacizumab in an adult undergoing treatment for stage IV colon cancer |
| Q34554398 | Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials |
| Q93039741 | Current Development of Monoclonal Antibodies in Cancer Therapy |
| Q48526422 | Dysregulated exocytosis of angiopoietin-2 drives cerebral cavernous malformation |
| Q31060162 | Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature |
| Q33594928 | Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis |
| Q26786618 | Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q36707182 | Efficacy and Toxicity Assessment of Different Antibody Based Antiangiogenic Drugs by Computational Docking Method |
| Q38285628 | Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature |
| Q53139590 | First description of an uterine perforation potentially imputable to treatment with bevacizumab. |
| Q53073357 | First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. |
| Q28086904 | Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy |
| Q48150990 | Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer. |
| Q55370438 | Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report. |
| Q35567689 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab |
| Q48212500 | Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer. |
| Q64072301 | Hernia and Cancer: The Points Where the Roads Intersect |
| Q36325837 | Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients |
| Q38005357 | Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers |
| Q37662388 | Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis |
| Q86494815 | Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated |
| Q96954293 | Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer |
| Q88636568 | Intestinal perforation after regorafenib usage |
| Q37711239 | Intestinal perforation in gynecologic oncology: do all patients benefit from surgical management? |
| Q84705056 | Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model |
| Q54541278 | Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. |
| Q36372377 | Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre |
| Q37737614 | Large-diameter self-expanding metal stents appear to be safe and effective for malignant colonic obstruction with and without concurrent use of chemotherapy |
| Q53091341 | Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. |
| Q26852509 | Lessons learned from the bevacizumab experience |
| Q62581024 | Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study |
| Q30417015 | Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. |
| Q26784531 | Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus |
| Q98613561 | Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report |
| Q26992174 | Medical management of brain tumors and the sequelae of treatment |
| Q44096551 | Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab |
| Q41451201 | Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report |
| Q38153444 | Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer |
| Q36318627 | NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy |
| Q83157132 | Nasal septum perforation and bevacizumab |
| Q34558472 | Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity. |
| Q39298030 | Nontraumatic large bowel perforation: spectrum of etiologies and CT findings |
| Q48828353 | Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers |
| Q47906624 | Overview of small bowel angioectasias: clinical presentation and treatment options. |
| Q38741548 | Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System |
| Q84511352 | Painful cervical esophageal erosion in a patient with advanced colorectal cancer treated with bevacizumab |
| Q37650308 | Palliative treatment of unresectable metastatic colorectal cancer |
| Q51249933 | Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy. |
| Q37081896 | Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma |
| Q91582017 | Pneumatosis Intestinalis After Molecular-Targeted Therapy |
| Q84354837 | Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib |
| Q47784587 | Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. |
| Q27015852 | Practical management of bevacizumab-related toxicities in glioblastoma |
| Q28252307 | Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer |
| Q59616684 | Progress against solid tumors in danger: the metastatic breast cancer example |
| Q92433317 | Pyopneumothorax during bevacizumab-containing chemotherapy in a patient with metastatic breast cancer |
| Q58705919 | Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer |
| Q30405727 | Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study |
| Q36008274 | Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials |
| Q37692420 | Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials |
| Q41650735 | Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials |
| Q38234800 | Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis |
| Q38184936 | Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. |
| Q35118673 | Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis |
| Q35622206 | Role of stenting in gastrointestinal benign and malignant diseases |
| Q36640122 | Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study |
| Q26823790 | Status and literature review of self-expandable metallic stents for malignant colorectal obstruction |
| Q58603126 | Stem cell enriched-epithelial spheroid cultures for rapidly assaying small intestinal radioprotectors and radiosensitizers in vitro |
| Q41112373 | Stercoral Ulcer-Associated Perforation and Chemotherapy |
| Q47105170 | Stereotactic body radiotherapy for primary and metastatic liver tumors - the Mayo Clinic experience |
| Q48219440 | Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. |
| Q38062459 | Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer |
| Q24193614 | Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration |
| Q43266641 | Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy |
| Q37795802 | Targeted Agents in Ovarian Cancer |
| Q37974894 | Targeted therapies for renal cell carcinoma: review of adverse event management strategies |
| Q59305026 | Targeted therapies in epithelial ovarian cancer |
| Q37702506 | Targeted therapy in gastrointestinal malignancies |
| Q36859868 | The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer |
| Q36526512 | The VEGF pathway in cancer and disease: responses, resistance, and the path forward. |
| Q35996651 | The current state of targeted agents in rectal cancer |
| Q42944599 | The effect of bevacizumab on colon anastomotic healing in rats |
| Q39154892 | The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study |
| Q89678320 | The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy |
| Q84227123 | The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab |
| Q37833645 | The role of bevacizumab in colorectal cancer: understanding its benefits and limitations |
| Q38810865 | The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer |
| Q38776999 | The safety of monoclonal antibodies for treatment of colorectal cancer |
| Q61805126 | Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study |
| Q85913643 | Ulcerative colitis in a patient with non-small-cell lung cancer receiving bevacizumab |
| Q89657254 | Unexplained isolated acute severe thrombocytopenia after surgery for a recurrent malignant retroperitoneal tumor presenting with colon perforation: A case study of a disastrous complication |
| Q37392026 | Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases |
| Q40898144 | Use of Vacuum-assisted closure in management of open abdominal wound with multiple enterocutaneous fistulae during chemotherapy: A case report |
| Q35076302 | Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity |
| Q36942426 | Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy |
| Q37695468 | Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care |
| Q38073812 | Vascular-disrupting agents in oncology |
| Q38016741 | What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents |
| Q54250253 | [Radiological imaging of acute infectious and non-infectious enterocolitis]. |
| Q82978669 | [The safety of perioperative bevacizumab use] |
Search more.